Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission
Journal of the American Geriatrics Society · 2025
DOI: 10.1111/jgs.70170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, 2025. Verfasst von Emily K Short und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Oregon State University College of Pharmacy, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Hospice Care, Drug Prescriptions, Hospices. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Themen: Palliativpflege
Abstract (Originalsprache)
Background
Little is known regarding antithrombotic prescribing in U.S. hospice patients. We quantified the prevalence and predictors of receiving an antithrombotic prescription on hospice admission.
Methods
This was a cross‐sectional study using electronic health record data from adult (age ≥ 18 years) decedents of a large, for‐profit hospice chain who died between January 1, 2017, and December 31, 2019. Our primary outcome was having a prescription for antithrombotic (anticoagulant or antiplatelet) therapy on hospice admission. We used multivariable logistic regression to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs).
Results
Among 54,643 hospice decedents, the mean age was 79.7 (standard deviation (SD) 13.2) years, 44.6% were male, and 57.0% were White. The median hospice length of stay was 9 (interquartile range 3–40) days, and 18,531 patients (33.9%) had a Palliative Performance Scale (PPS) score of 30%. Overall, 11,360 patients (20.8%) had at least one antithrombotic prescription on hospice admission. The most frequently prescribed antithrombotic classes were antiplatelets (15.7%) and direct oral anticoagulants (3.7%). Patients with PPS scores of 20%–30% (adjusted OR (aOR) 9.38, 95% CI 8.03–10.95), 40%–50% (aOR 15.69, 95% CI 13.38–18.40), and 60%–100% (aOR 15.67, 95% CI 12.41–19.79) were significantly more likely to receive an antithrombotic prescription compared to patients with a PPS score < 20%. Additionally, patients receiving care in an assisted living facility (aOR 4.34, 95% CI 3.86–4.87), nursing home (aOR 4.02, 95% CI 3.62–4.47), or at home (aOR 4.08, 95% CI 3.74–4.45) were more likely to receive an antithrombotic prescription compared to patients receiving care in an inpatient hospice setting.
Conclusions
Antithrombotic therapy was prevalent on hospice admission and most associated with better patient prognosis and non‐inpatient hospice care locations. More research is needed to optimize antithrombotic prescribing in hospice care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Oregon State University College of Pharmacy, Portland, Oregon, USA.
- Division of Epidemiology, Department of Population and Quantitative Health Services, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Department of Pharmacy Practice, Sciences, and Health Outcomes, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
ORCID-Profile: Emily K Short, Jon P Furuno
Zitieren
APA
Short, E. K., Duong, P. Y., Tjia, J., Alcusky, M., McPherson, M. L., & Furuno, J. P. (2025). Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.70170
Vancouver
Short EK, Duong PY, Tjia J, Alcusky M, McPherson ML, Furuno JP. Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission. Journal of the American Geriatrics Society. 2025. doi:10.1111/jgs.70170
BibTeX
@article{Short2025,
author = {Short, Emily K and Duong, Phuong Y and Tjia, Jennifer and Alcusky, Matthew and McPherson, Mary Lynn and Furuno, Jon P},
title = {Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission},
journal = {Journal of the American Geriatrics Society},
year = {2025},
doi = {10.1111/jgs.70170}
}
EUVIMED